Prof. David Scott Miller

powered by
COS Expertise®
University of Texas Southwestern Medical Center at Dallas
Southwestern Medical School
ProfessorAppointed: 1998
University of Texas Southwestern Medical Center at Dallas
Southwestern Medical School
Dallas Foundation Chair in Gynecologic OncologyAppointed: 1994
Parkland Memorial Hospital
Women & Children's Health
Gynecologic Oncology
Medical DirectorAppointed: 1991
University of Texas Southwestern Medical Center at Dallas
Gynecologic Oncology
DirectorAppointed: 1991
Professional Headshot of David Scott Miller

Mailing Address

Division of Gynecologic Oncology
Department of Obstetrics & Gynecology
University of Texas Southwestern Medical Center
5323 Harry Hines Blvd., #J7.124
Dallas, Texas 75390-9032
United States

Contact Information

Phone: (214) 648-3026
Fax: (214) 648-8404
David.Miller@UTSouthwestern.edu
http://www8.utsouthwestern.edu/finddoc/professional/0,2364,14954,00.html

Qualifications

F.A.C.S., American College of Surgeons, 1988.
F.A.C.O.G., American College of Obststricians & Gynecologists, 1987.
Fellowship, Stanford University, Gynecologic Oncology, 1985.
Residency, Medical College of Pennsylvania, Obstetrics & Gynecology, 1981.
M.D., University of Oklahoma, 1977.

Expertise and Research Interests

Ovarian neoplasms
Uterine neoplasm
Endometrial neoplasms
Cervical neoplasms
Cervical cancer screening and prevention
Vaginal neoplasms
Vulvar neoplasms
Trophoblastic tumors
Phase II trials
Minimally invasive surgery
Gynecologic oncology
Topotecan
9-Aminocamptothecin
Pemetrexed (Alimta)

Other Expertise

University of California, San Diego, Reproductive Endocrinology, Fellowship, 1982
Stanford University, Gynecologic Oncology, Fellowship, 1985
Residency, Hospital of the Medical College of Pennsylvania, Obstetrics & Gynecology, 1981

Keywords

COS Keywords:

Cancer Or Carcinogenesis, Clinical Trial, Gene Therapy, Neoplasm, Obstetrics Or Gynecology, Oncology, Ovarian Cancer, Reproductive Endocrinology, Tumors.

Additional Terms:

Cervical Cancer, Clinical Trials, Endometrial Cancer, Gene Therapy, Gestational Trophoblastic Disease, Gynecologic Oncology, Ovarian Cancer, Phase II Trial, Phase III Trial, Trophoblastic Tumors, Uterine Sarcomas.

Languages

(Reading, Writing, Speaking)

English: (Fluent, Fluent, Fluent)

Memberships

American College of Obstetricians and Gynecologists
American College of Surgeons
American Radium Society
American Society of Clinical Oncology
Association of Professors of Gynecology and Obstetrics
Association of Reproductive Health Professionals
Dallas County Medical Society
Gynecologic Oncology Group
International Gynecologic Cancer Society
Society of Gynecologic Oncologists
Texas Medical Association
Western Association of Gynecologic Oncologists

Honors and Awards

2006, The Best Doctors in Dallas Award, D Magazine
2005-2006, Texas Super Doctors, Texas Monthly
2003, The Best Doctors in Dallas Award, D Magazine
2000, National Faculty Award for Excellence in Resident Education, Council on Resident Education in Obstetrics & Gynecology
1999-2000, Senior Residents Award for Outstanding Faculty Teacher, University of Texas Southwestern Medical Center at Dallas
1991, First Prize Scientific Paper Award, American College of Obstetricians & Gynecologists, 39th Annual Meeting, New Orleans, LA
1990-1991, Magnus P Urnes, M.D. Resident Teaching Award, Northwestern Memorial Hospital, Northwestern University
1987-1990, Clinical Oncology Career Development Award, American Cancer Society
1985, Armand Hammer Travel Award, James Ewing Foundation, Society of Surgical Oncology
1980-1981, Golden Apple Award, Class of 1981, Medical College of Pennsylvania, Excellence in medical student teaching

Previous Positions

1991-1998, Associate Professor, University of Texas Southwestern Medical Center at Dallas, Southwestern Medical School, Obstetrics and Gynecology
1985-1991, Assistant Professor, Northwestern University, Obstetrics and Gynecology, Gynecologic Oncology
1983-1985, Fellowship, Stanford University, Gynecologic Oncology
1982-1983, Assistant Professor, Medical University of South Carolina, Obstetrics and Gynecology
1982-1982, Fellowship, University of California, San Diego, School of Medicine, Reproductive Endocrinology
1981-1982, Assistant Instructor, University of California, San Diego, School of Medicine, Reproductive Medicine
1977-1981, Resident, Hospital of the Medical College of Pennsylvania, Obstetrics and Gynecology

Publications

  • Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV, Gynecologic Oncology Group Study (Jul 2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study., Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 23 (21), 4626-33 Abstract
  • Lavie I, Rao GG, Castrillon DH, Miller DS, Schorge JO, Duration of Human Chorionic Gonadotropin Surveillance for Partial Hydatidiform Moles., American Journal of Obstetrics and Gynecology, 192(5), 1362-4, May 2005 Abstract
  • Rao GG, Miller DS, Clinical Applications of Hormonal Therapy in Ovarian Cancer., Current Treatment Options in Oncology, 6(2), 97-102, Mar 2005 Abstract
  • Garcia AA, Blessing JA, Lenz HJ, Darcy KM, Mannel RS, Miller DS, Husseinzadeh N, Gynecologic Oncology Group, Phase II Clinical Trial of Capecitabine in Ovarian Carcinoma Recurrent 6-12 Months After Completion of Primary Chemotherapy, With Exploratory TS, DPD, and TP Correlates: a Gynecologic Oncology Group Study., Gynecologic Oncology, 96(3), 810-7, Mar 2005 Abstract
  • Miller DS, Blessing JA, Waggoner S, Schilder J, Sorosky J, Bloss J, Schilder R, Phase II Evaluation of 9-aminocamptothecin (9-AC, NSC #603071) In Platinum-resistant Ovarian and Primary Peritoneal Carcinoma: a Gynecologic Oncology Group Study., Gynecologic Oncology, 96(1), 67-71, Jan 2005 Abstract
  • Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF, Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study, Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 22(15), 3113-9, Aug 2004 Abstract
  • Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL, Oral Dexamethasone Attenuates Doxil-induced Palmar-plantar Erythrodysesthesias in Patients With Recurrent Gynecologic Malignancies., Gynecologic Oncology, 94(2), 320-4, Aug 2004 Abstract
  • Lea JS, Ashfaq R, Muneer S, Burbee DG, Miller DS, Minna JD, Muller CY, Understanding the Mechanisms of FHIT Inactivation in Cervical Cancer For Biomarker Development., Journal of the Society for Gynecologic Investigation, 11(5), 329-37, Jul 2004 Abstract
  • Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim JH, Cramer DW, Berkowitz RS, Mok SC, Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer, Clinical Cancer Research : an Official Journal of the American Association for Cancer Research., 10(10), 3474-8, May 2004 Abstract
  • Delin JB, Miller DS, Coleman RL, Other Primary Malignancies in Patients With Uterine Corpus Malignancy., American Journal of Obstetrics and Gynecology, 190(5), 1429-31, May 2004 Abstract
  • Lea JS, Coleman R, Kurien A, Schorge JO, Miller DS, Minna JD, Muller CY, Aberrant P16 Methylation Is a Biomarker for Tobacco Exposure in Cervical Squamous Cell Carcinogenesis., American Journal of Obstetrics and Gynecology, 190(3), 674-9, Mar 2004 Abstract
  • Schorge JO, Lea JS, Elias KJ, Rajanbabu R, Coleman RL, Miller DS, Ashfaq R, P16 As a Molecular Biomarker of Cervical Adenocarcinoma., American Journal of Obstetrics and Gynecology, 190(3), 668-73, Mar 2004 Abstract
  • Muggia FM, Blessing JA, Method M, Miller DS, Johnson GA, Lee RB, Menzin A, Gynecologic Oncology Group study, Evaluation of Vinorelbine in Persistent Or Recurrent Squamous Cell Carcinoma of the Cervix: a Gynecologic Oncology Group Study., Gynecologic Oncology, 92(2), 639-43, Feb 2004 Abstract
  • Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC Jr, Tezcan H, Waples J, Ward J, Yee LK, A Randomized Controlled Trial of Darbepoetin Alfa Administered As a Fixed Or Weight-based Dose Using a Front-loading Schedule in Patients With Anemia Who Have Nonmyeloid Malignancies., Cancer, 100(4), 859-68, Feb 2004 Abstract
  • Lea JS, Coleman RL, Garner EO, Duska LR, Miller DS, Schorge JO, Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma, Gynecologic Oncology, 91(3), 558-62, 2003 Abstract
  • Miller DS, Blessing JA, Lentz SS, McMeekin DS, Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: A gynecologic oncology group study, Cancer, 98(8), 1664-9, October 2003
  • Schorge JO, Lea JS, Farrar DF, King MR, Coleman RL, Miller DS, Management of low-risk gestational trophoblastic neoplasia in indigent women, The Journal of Reproductive Medicine, 48(10), 780-4, October 2003 Abstract
  • Jaiswal VR, Baird J, Fleming J, Miller DS, Sharma S, Molberg K, Localized retroperitoneal lymphangioleiomyomatosis mimicking malignancy. A case report and review of the literature, Archives of Pathology and Laboratory Medicine, 127(7), 879-82, July 2003 Abstract
  • Allen JE, King MR, Farrar DF, Miller DS, Schorge JO, Postmolar Surveillance At a Trophoblastic Disease Center That Serves Indigent Women., American Journal of Obstetrics and Gynecology, 188(5), 1151-3, May 2003 Abstract
  • Schorge JO, Lea JS, Garner EO, Duska LR, Miller DS, Coleman RL, Cervical Adenocarcinoma Survival Among Hispanic and White Women: A Multicenter Cohort Study., American Journal of Obstetrics and Gynecology, 188(3), 640-4, Mar 2003 Abstract
  • Miller DS, Blessing JA, Lentz SS, Waggoner SE, A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study, Gynecologic Oncology, 87(3), 247-51, Dec 2002 Abstract
  • Lea JS, Shin CH, Sheets EE, Coleman RL, Gehrig PA, Duska LR, Miller DS, Schorge JO, Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ, Gynecologic Oncology, 87(1), 129-32, October 2002 Abstract
  • Wai CY, Miller DS, Urinary bladder cancer, Clinical Obstetrics and Gynecology, 45(3), 844-54, September 2002 Abstract
  • Edmonson JH, Blessing JA, Cosin JA, Miller DS, Cohn DE, Rotmensch J, Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study, Gynecologic Oncology, 85(3), 507-10, June 2002 Abstract
  • Lea JS, Sheets EE, Duska LR, Miller DS, Schorge JO, Early-stage cervical adenocarcinoma treated by surgical intent: the role of para-aortic lymph node dissection, Gynecologic Oncology, 84(2), 285-8, February 2002 Abstract
  • Lea JS, Sheets EE, Wenham RM, Duska LR, Coleman RL, Miller DS, Schorge JO, Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival, Gynecologic Oncology, 84(1), 115-9, Jan 2002 Abstract
  • Schorge JO, Mahoney NM, Miller DS, Coleman RL, Muller CY, Euhus DM, Tomlinson GE, Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer, Gynecologic Oncology, 83(2), 383-7, November 2001 Abstract
  • Lea JS, Miller DS, Optimum screening interventions for gynecologic malignancies, Texas Medicine, 97(2), 49-55, February 2001 Abstract
  • O'Boyle JD, Coleman RL, Bernstein SG, Lifshitz S, Muller CY, Miller DS, Intraoperative lymphatic mapping in cervix cancer patients undergoing radical hysterectomy: A pilot study, Gynecologic Oncology, 79(2), 238-43, November 2000 Abstract
  • Sherwood JB, Shivapurkar N, Lin WM, Ashfaq R, Miller DS, Gazdar AF, Muller CY, Chromosome 4 deletions are frequent in invasive cervical cancer and differ between histologic variants, Gynecologic Oncology, 79(1), 90-6, October 2000 Abstract
  • Miller DS, Blessing JA, Kilgore LC, Mannel R, Van Le L, Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study, American Journal of Clinical Oncology, 23(4), 355-7, August 2000 Abstract
  • Von Gruenigen VE, Coleman RL, Li AJ, Heard MC, Miller DS, Hemsell DL, Bacteriology and treatment of malodorous lower reproductive tract in gynecologic cancer patients, Obstetrics and Gynecology, 96(1), 23-7, July 2000 Abstract
  • Sinkre P, Miller DS, Milchgrub S, Hameed A, Adenomyofibroma of the endometrium with skeletal muscle differentiation, International Journal of Gynecological Pathology, 19(3), 280-3, July 2000 Abstract
  • Sinkre P, Milchgrub S, Miller DS, Albores-Saavedra J, Hameed A, Uterine metastasis from a heterologous metaplastic breast carcinoma simulating a primary uterine malignancy, Gynecologic Oncology, 77(1), 216-8, April 2000 Abstract
  • Sinkre P, Albores-Saavedra J, Miller DS, Copeland LJ, Hameed A, Endometrial endometrioid carcinomas associated with Ewing sarcoma/peripheral primitive neuroectodermal tumor, International Journal of Gynecological Pathology, 19(2), 127-32, April 2000 Abstract
  • Coleman RL, Lindberg G, Muller CY, Miller DS, Hameed A, Ectopic production and localization of beta-human chorionic gonadotropin in lymphoepithelioma-like carcinoma of the cervix: a case report, International Journal of Gynecological Pathology, 19(2), 179-82, April 2000 Abstract
  • O'Boyle JD, Proctor ML, Fong KM, Lin WM, Miller DS, Muller CY, Role of TSG101 in uterine cervix cancer, Gynecologic Oncology, 75(3), 401-5, December 1999 Abstract
  • Twickler DM, Forte TB, Santos-Ramos R, McIntire D, Harris P, Miller DS, The Ovarian Tumor Index predicts risk for malignancy, Cancer, 86(11), 2280-90, December 1999 Abstract
  • von Gruenigen VE, Coleman RL, King MR, Miller DS, Abdominal compartment syndrome in gynecologic surgery, Obstetrics and Gynecology, 94(5 Pt 2), 830-2, November 1999 Abstract
  • Hameed A, Miller DS, Muller CY, Coleman RL, Albores-Saavedra J, Frequent expression of beta-human chorionic gonadotropin (beta-hCG) in squamous cell carcinoma of the cervix, International Journal of Gynecological Pathology, 18(4), 381-6, October 1999 Abstract
  • Flowers LC, Wistuba II, Scurry J, Muller CY, Ashfaq R, Miller DS, Minna JD, Gazdar AF, Genetic changes during the multistage pathogenesis of human papillomavirus positive and negative vulvar carcinomas, Journal of the Society for Gynecologic Investigation, 6(4), 213-21, 1999 Abstract
  • Santoso JT, Lucci JA 3rd, Coleman RL, Hatch S, Wong P, Miller D, Mathis JM, Does glutamine supplementation increase radioresistance in squamous cell carcinoma of the cervix?, Gynecologic Oncology, 71(3), 359-63, December 1998 Abstract
  • von Gruenigen VE, Santoso JT, Coleman RL, Muller CY, Miller DS, Mathis JM, In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer, Gynecologic Oncology, 69(3), 197-204, June 1998 Abstract
  • Santoso JT, Coleman RL, Voet RL, Bernstein SG, Lifshitz S, Miller D, Pathology slide review in gynecologic oncology, Obstetrics and Gynecology, 91(5 Pt 1), 730-4, May 1998 Abstract
  • Muller CY, O'Boyle JD, Fong KM, Wistuba II, Biesterveld E, Ahmadian M, Miller DS, Gazdar AF, Minna JD, Abnormalities of fragile histidine triad genomic and complementary DNAs in cervical cancer: association with human papillomavirus type, Journal of the National Cancer Institute, 90(6), 433-9, March 1998 Abstract
  • Thai TH, Du F, Tsan JT, Jin Y, Phung A, Spillman MA, Massa HF, Muller CY, Ashfaq R, Mathis JM, Miller DS, Trask BJ, Baer R, Bowcock AM, Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers, Human Molecular Genetics, 7(2), 195-202, February 1998 Abstract
  • Coleman RL, Miller DS, Topotecan in the treatment of gynecologic cancer., Seminars in Oncology, 24(6 Suppl 20), S20-55-S20-63, December 1997 Abstract
  • Shivvers SA, Miller DS, Preinvasive and invasive breast and cervical cancer prior to or during pregnancy., Clinics in Perinatology, 24(2), 369-89, June 1997 Abstract
  • Tait DL, Miller DS, Multicystic ovarian tumor weighing 156 lbs: the second largest tumor in Texas, Texas Medicine, 93(1), 89-91, January 1997 Abstract
  • Kutteh WH, Miller DS, Mathis JM, Immunologic characterization of tumor markers in human ovarian cancer cell lines, Journal of the Society for Gynecologic Investigation, 3(4), 216-22, 1996 Abstract
  • Santoso J T, Tang D C, Lane S B, Hung J, Reed D J, Muller C Y, Carbone D P, Lucci J A 3rd, Miller D S, Mathis J M, Adenovirus-based p53 gene therapy in ovarian cancer, Gynecologic Oncology, 59(2), 171-8, November 1995 Abstract
  • Santoso JT, Tang DC, Lane SB, Hung J, Reed DJ, Muller CY, Carbone DP, Lucci JA 3rd, Miller DS, Mathis JM, Adenovirus-based p53 gene therapy in ovarian cancer [see comments, Gynecologic Oncology, 59(2), 171-8, November 1995 Abstract
  • Santoso JT, Lin DW, Miller DS, Transfusion medicine in obstetrics and gynecology, Obstetrical and Gynecological Survey, 50(6), 470-81, June 1995 Abstract
  • Economos K, Lucci JA 3rd, Richardson B, Yazigi R, Miller DS, The effect of naproxen on fever in patients with advanced gynecologic malignancies, Gynecologic Oncology, 56(2), 250-4, February 1995 Abstract
  • Bulun SE, Economos K, Miller D, Simpson ER, CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors, Journal of Clinical Endocrinology and Metabolism, 79(6), 1831-4, December 1994 Abstract
  • Szela E, Bachicha J, Miller D, Till M, Wilson JB, Schistosomiasis and cervical cancer in Ghana, International Journal of Gynaecology and Obstetrics, 42(2), 127-30, August 1993 Abstract
  • Coleman RL, Schink JC, Miller DS, Bauer KD, August CZ, Rademaker AW, Lurain JR, DNA flow cytometric analysis of clinical stage I endometrial carcinomas with lymph node metastases, Gynecologic Oncology, 50(1), 20-4, July 1993 Abstract
  • Connor JP, Miller DS, Bauer KD, Murad TM, Rademaker AW, Lurain JR, Flow cytometric evaluation of early invasive cervical cancer, Obstetrics and Gynecology, 81(3), 367-71, March 1993 Abstract
  • Schink JC, Singh DK, Rademaker AW, Miller DS, Lurain JR, Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease, Obstetrics and Gynecology, 80(5), 817-20, November 1992 Abstract
  • Miller DS, Brady MF, Barrett RJ, A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study, American Journal of Clinical Oncology, 15(2), 125-8, April 1992 Abstract
  • Miller DS, Spirtos NM, Ballon SC, Cox RS, Soriero OM, Teng NN, Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value in patients with persistent cancer, Cancer, 69(2), 502-10, January 1992 Abstract
  • Deicas RE, Miller DS, Rademaker AW, Lurain JR, The role of contraception in the development of postmolar gestational trophoblastic tumor, Obstetrics and Gynecology, 78(2), 221-6, August 1991 Abstract
  • Lurain JR, Rice BL, Rademaker AW, Poggensee LE, Schink JC, Miller DS, Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium, Obstetrics and Gynecology, 78(1), 63-9, July 1991 Abstract
  • Schink JC, Rademaker AW, Miller DS, Lurain JR, Tumor size in endometrial cancer, Cancer, 67(11), 2791-4, June 1991 Abstract
  • Lawson SR, Latter G, Miller DS, Goldstein D, Naps M, Burbeck S, Teng NN, Zuckerkandl E, Quantitative protein changes in metastatic versus primary epithelial ovarian carcinoma, Gynecologic Oncology, 41(1), 22-7, April 1991 Abstract
  • Lurain JR, Casanova LA, Miller DS, Rademaker AW, Prognostic factors in gestational trophoblastic tumors: a proposed new scoring system based on multivariate analysis, American Journal of Obstetrics and Gynecology, 164(2), 611-6, February 1991 Abstract
  • Eriksen B, Miller DS, Murad TM, Lurain JR, Bauer KD, Dual-parameter flow cytometric analysis coupling the measurements of forward-angle light scatter and DNA content of archival ovarian carcinomas of low malignant potential, Analytical and Quantitative Cytology and Histology, 13(1), 45-53, February 1991 Abstract
  • Christman JE, Miller DS, Coward P, Smith LH, Teng NN, Study of the selective cytotoxic properties of cationic, lipophilic mitochondrial-specific compounds in gynecologic malignancies, Gynecologic Oncology, 39(1), 72-9, October 1990 Abstract
  • Barnabei VM, Miller DS, Bauer KD, Murad TM, Rademaker AW, Lurain JR, Flow cytometric evaluation of epithelial ovarian cancer, American Journal of Obstetrics and Gynecology, 162(6), 1584-90; discussion, June 1990 Abstract
  • Miller DS, Seifer DB, Endocrinologic aspects of gestational trophoblastic diseases, International Journal of Fertility, 35(3), 137-53, May 1990 Abstract
  • Miller DS, Lurain JR, Classification and staging of gestational trophoblastic tumors, Obstetrics and Gynecology Clinics of North America, 15(3), 477-90, September 1988 Abstract
  • Miller DS, Teng NN, Ballon SC, Epithelial ovarian carcinoma in patients with intersex disorders: the role of pituitary gonadotropins in ovarian tumorigenesis, Gynecologic Oncology, 24(3), 299-308, July 1986 Abstract
  • Miller DS, Ballon SC, Teng NN, Seifer DB, Soriero OM, A critical reassessment of second-look laparotomy in epithelial ovarian carcinoma, Cancer, 57(3), 530-5, February 1986 Abstract
  • Miller DS, Reid RR, Cetel NS, Rebar RW, Yen SS, Pulsatile administration of low-dose gonadotropin-releasing hormone. Ovulation and pregnancy in women with hypothalamic amenorrhea, Jama, 250(21), 2937-41, December 1983 Abstract
  • Miller DS, The use of the laser in gynecology, Journal of the South Carolina Medical Association, 79(11), 627-30, November 1983 Abstract

Profile Details

Last Verified: 11/1/2006

COS Expertise ID #133526
Reference this profile directly: http://myprofile.cos.com/miller26